To quantify changes in graft utilization, specifically haplo-BM and haplo-PBSC versus UCB, following the publication of the CTN-1101 trial (2012-2018).
Key Findings:
Increased utilization of haplo transplants and decreased utilization of UCB transplants from 2009 to 2019.
Haplo-BM showed better two-year overall survival compared to double UCB (57% vs 46%; p = 0.04).
Five-year survival was higher after non-trial haplo-BM compared to trial double UCB (47% vs 36%; p = 0.012).
Interpretation:
The findings suggest a shift in clinical practice towards haploidentical grafts following the CTN-1101 trial, indicating improved access to transplants, particularly for patients without optimal donor matches.
Limitations:
The study only included U.S. patients and did not account for international trends.
Exclusions of certain patient groups may limit the generalizability of the findings.
The retrospective nature of the study may introduce biases.
Conclusion:
The analysis highlights significant changes in graft utilization patterns post-CTN-1101, supporting the relevance of clinical trial data in influencing real-world practices.
One of the most promising developments in advanced-stage Hodgkin lymphoma is the nivolumab-AVD regimen, which combines nivolumab with doxorubicin, vinblastine, and dacarbazine. This article provides practical knowledge for advanced practitioners to effectively manage the most common toxicities associated with nivolumab-AVD.
